Fundraising FoxTiga Tx
2 known investors
Find your way into Tiga Tx
Sign up to see every warm intro you have to Tiga Tx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tiga Tx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach. The company focuses on first-in-class immunotherapy for cancer patients.
Investors · 2
BioGeneration Ventureslisted by BioGeneration VenturesNaarden
How we know: BioGeneration Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Related companies · 5
G1 TherapeuticsG1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
LactigaLactiga is a biotechnology company developing mucosal antibody therapies based on secretory IgA antibodies derived from human breastmilk. Its platform targets conditions such as chronic respiratory disorders, gut inflammation, and immune deficiencies through mucosal immunotherapy.
Apogee TherapeuticsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
GC TherapeuticsGCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling. The platform is designed to expand patient access to cell therapies across various therapeutic areas.
Gain TherapeuticsGain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.
Companies working in the same space as Tiga Tx.
Frequently asked questions
- What does Tiga Tx do?
- Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach. The company focuses on first-in-class immunotherapy for cancer patients.
- Who are Tiga Tx's investors?
- Tiga Tx's investors include BioGeneration Ventures, Civilization Ventures Management, Llc.